

RECEIVED  
CENTRAL FAX CENTER

DEC 04 2006

Attorney Docket No. 022052-000700US

PTO FAX NO.: (571) 273-8300

ATTENTION: Examiner J. Graser  
TELEPHONE NO.: (571) 272-0858

Group Art Unit 1645

## OFFICIAL COMMUNICATION

### CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following document regarding Application No. 09/844,281, filed April 30, 2001 is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

#### Document(s) Attached

1. Response under 37 CFR 1.116

Number of pages being transmitted, including this page: 13

Dated: December 4, 2006

  
Kawai Lau

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300*

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: (858) 350-6100  
Fax: (415) 576-0300  
60930863 v1

**RECEIVED**  
**CENTRAL FAX CENTER**

DEC 04 2006

I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark Office,  
Fax No. 1-571-273-8300 on 12/4/06.

**AMENDMENT UNDER 37 CFR 1.116**  
**EXPEDITED PROCEDURE -**  
**EXAMINING GROUP 1645**

TOWNSEND and TOWNSEND and CREW LLP

By: 

Kuwah Lau

**PATENT**  
Attorney Docket No.: 022052-000700US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Beverly Lynn Mangold, et al.

Application No.: 09/844,281

Filed: April 30, 2001

For: ANTHRAX SPECIFIC  
ANTIBODIES

Customer No.: 20350

Confirmation No. 1022

Examiner: Jennifer E. Graser

Technology Center/Art Unit: 1645

**AMENDMENT UNDER 37 C.F.R. 1.116**  
**EXPEDITED PROCEDURE EXAMINING**  
**GROUP 1645**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the "final" Office Action mailed October 3, 2006, which set January 3, 2007 as the initial deadline for response. This Reply, filed Monday, December 04, 2006, is thus believed to be timely filed within two months of October 3, 2006.

Reconsideration in light of the following revisions and remarks is respectfully requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.